Author:
Grau Gerard,Altadill Ariadna,Brunet-Mas Eduard,Calvet Xavier
Subject
Gastroenterology,Hepatology
Reference8 articles.
1. Immune checkpoint inhibitor-induced colitis: a comprehensive review;Som;World J Clin Cases,2019
2. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review;Gong;JCO Oncol Pract,2020
3. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?;Vasudevan;World J Gastroenterol,2017
4. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial;Danese;Clin Gastroenterol Hepatol.,2022
5. Agencia Española de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terapéutico de Ustekinumab (Stelara®) en el tratamiento de la colitis ulcerosa moderada - grave. 8 de octubre de 2021. Disponible en: https://www.aemps.gob.es/informa/informes-de-posicionamiento-terapeutico/informe-de-posicionamiento-terapeutico-de-ustekinumab-stelara-en-el-tratamiento-de-la-colitis-ulcerosa-moderada-grave/#